Analysis of the characteristics of primary acute myeloid leukemia with 11q23/KMT2A rearrangements in ninety patients.
10.3760/cma.j.cn511374-20220817-00556
- Author:
Ye LI
1
;
Yanlin WANG
;
Zheng WANG
;
Lin FENG
;
Lu GAO
;
Yan SHI
;
Hui DANG
;
Qi HE
;
Yazhen QIN
;
Qian JIANG
;
Hao JIANG
;
Xiaojun HUANG
;
Yueyun LAI
Author Information
1. Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China. laiyueyun1008@sina.com.
- Publication Type:Journal Article
- MeSH:
Humans;
Retrospective Studies;
Leukemia, Myeloid, Acute/therapy*;
Translocation, Genetic;
Gene Rearrangement;
Prognosis
- From:
Chinese Journal of Medical Genetics
2023;40(12):1472-1477
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical and prognostic characteristics of primary acute myeloid leukemia (AML) with 11q23/KMT2A rearrangements.
METHODS:Clinical data of 90 patients with primary AML and 11q23/KMT2A rearrangements were analyzed retrospectively.
RESULTS:By karyotyping analysis, 80 of the 90 patients had translocations involving 11q23/KMT2A, with t(9;11)(p22;q23), t(6;11)(q27;q23), t(10;11)(p12;q23) and t(11;19)(q23;p13) being the most common ones, while 10 cases were found to have non-translocation abnormalities. The overall complete remission (CR) rate was 75.6%, and patients with t(6;11) had lower CR rate compared with non-t(6;11) patients (47.1% vs. 82.2%, P = 0.005). After a median follow-up of 24.5 months, the patients receiving allo-hematopoietic stem cell transplantation (allo-HSCT) had significantly higher 3-year overall survival (OS) (80.3% vs. 16.6%, P < 0.001) and 3-year event-free survival (EFS) (73.5% vs. 16.3%, P < 0.001) compared with non-transplant patients. Patients with t(6;11) had the lowest 3-year OS (11.8% vs. 56.0%, P < 0.001) and 3-year EFS (5.9% vs. 53.8%, P < 0.001) compared with other type of abnormalities. No significant difference was noted in the survival between patients with t(9;11) and non-t(9;11) regardless whether they had received HSCT.
CONCLUSION:The clinical characteristics of primary AML with 11q23/KMT2A rearrangements are heterogeneous. Patients did not receive HSCT had poorer survival, particularly with the presence of t(6;11). Allo-HSCT could significantly improve the survival of such patients.
